972 related articles for article (PubMed ID: 22498825)
1. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
2. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
4. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
5. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
6. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
8. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
9. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
10. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
11. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
12. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
[TBL] [Abstract][Full Text] [Related]
13. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
14. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
15. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
16. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53 overexpression in endometrial cancer.
Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
Cancer Res; 1994 Sep; 54(17):4667-70. PubMed ID: 8062261
[TBL] [Abstract][Full Text] [Related]
18. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry.
Santacana M; Maiques O; Valls J; Gatius S; Abó AI; López-García MÁ; Mota A; Reventós J; Moreno-Bueno G; Palacios J; Bartosch C; Dolcet X; Matias-Guiu X
Hum Pathol; 2014 Dec; 45(12):2394-403. PubMed ID: 25282036
[TBL] [Abstract][Full Text] [Related]
19. Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases.
Culton LK; Deavers MT; Silva EG; Liu J; Malpica A
Am J Surg Pathol; 2006 Jul; 30(7):844-9. PubMed ID: 16819326
[TBL] [Abstract][Full Text] [Related]
20. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]